ForPatients
by Roche

Multiple Myeloma

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Trial Status	Trial Runs In	Trial Identifier
Active, not recruiting	1 Country	NCT03741127 GO46334 P-BCMA-101-002

The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.

Official Title:

Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Trial Summary:

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03741127 GO46334 P-BCMA-101-002
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#18 Years	No

Inclusion Criteria:

- Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.
- Subject has provided informed consent.

© 2022 F. Hoffmann-La Roche Ltd

Exclusion Criteria:

- None

© 2022 F. Hoffmann-La Roche Ltd